Valuation: Sigyn Therapeutics, Inc.

Market Cap 2.75M 2.5M 2.3M 2.1M 3.93M 254M 4.13M 28.04M 11.14M 139M 10.3M 10.08M 436M P/E 2023
-1.25x
P/E 2024 -1.25x
Enterprise Value 4.93M 4.49M 4.13M 3.76M 7.05M 456M 7.41M 50.31M 19.99M 249M 18.48M 18.09M 782M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
78.99%
Yield 2023 *
-
Yield 2024 -
1 day-18.97%
1 week+13.67%
Current month+13.67%
1 month+5.33%
3 months+26.40%
6 months-19.80%
Current year-98.15%
1 week 0.03
Extreme 0.0269
0.03
1 month 0.03
Extreme 0.0269
0.03
Current year 0.01
Extreme 0.0103
1.25
1 year 0.01
Extreme 0.0103
2
3 years 0.01
Extreme 0.0103
7.96
5 years 0.01
Extreme 0.0103
30.4
10 years 0.01
Extreme 0.0103
140
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 73 19/10/2019
Chief Executive Officer 64 19/10/2019
Chief Tech/Sci/R&D Officer - 26/01/2021
Director TitleAgeSince
Chairman 64 19/10/2019
Director/Board Member 73 19/10/2019
Director/Board Member 71 10/10/2022
Change 5-day change 1-year change 3-year change Capi.($)
-18.97%+13.67%-97.74%-99.56% 147K
-0.84%-5.09%-16.92%+1.78% 178B
-0.67%-2.84%+0.59%+32.97% 122B
-0.98%+0.12%-14.00%+7.16% 118B
-1.24%-4.25%-43.89%-1.12% 88.1B
-0.63%-5.55%-6.35%+73.06% 64.71B
+0.05%-2.41%+12.24%-8.94% 57.96B
-1.95%-3.98%-1.91%+42.98% 53.28B
-2.91%-4.35%-0.82%+38.03% 47.8B
-1.64%+1.50%+2.30%-1.14% 35.65B
Average -2.98%-2.36%-16.65%+8.52% 77B
Weighted average by Cap. -1.04%-2.97%-10.73%+17.45%

Financials

2023 2024
Net sales - -
Net income -4.15M -3.78M -3.48M -3.17M -5.94M -384M -6.24M -42.35M -16.83M -210M -15.56M -15.23M -658M -3.34M -3.04M -2.8M -2.55M -4.78M -309M -5.03M -34.12M -13.56M -169M -12.53M -12.27M -530M
Net Debt 2.47M 2.25M 2.07M 1.88M 3.53M 228M 3.71M 25.19M 10.01M 125M 9.25M 9.06M 391M 2.18M 1.99M 1.83M 1.66M 3.12M 202M 3.28M 22.27M 8.85M 110M 8.18M 8.01M 346M
Projected Income Statement - Annual - Sigyn Therapeutics, Inc.
Logo Sigyn Therapeutics, Inc.
Sigyn Therapeutics, Inc. develops medical devices to treat cancer and infectious disease disorders. The Company's lead therapeutic candidate, Sigyn Therapy, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders. Candidate treatment indications include endotoxemia and inflammation in end-stage renal disease (dialysis) patients, sepsis (a cause of hospital deaths), community-acquired pneumonia (a cause of death among infectious diseases), and emerging pandemic threats. Sigyn Therapy is a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines. Its development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the tumor site delivery of chemotherapy, and ChemoPure to reduce treatment toxicity and inhibit the spread of cancer metastasis. Its ImmunePrep platform enhances the performance of immunotherapeutic antibodies.
Employees
-
Date Price Change Volume
18/11/26 $0.0276 +2.42% 18,166
17/11/26 $0.0269 -.--% 20,000
  1. Stock Market
  2. Stocks
  3. SIGY Stock